119 related articles for article (PubMed ID: 8857669)
1. Monoclonal antibody MAT-1 against human tyrosinase can detect melanogenic cells on formalin-fixed paraffin-embedded sections.
Sato N; Suzuki S; Takimoto H; Masui S; Shibata K; Nakano H; Tomita Y
Pigment Cell Res; 1996 Apr; 9(2):72-6. PubMed ID: 8857669
[TBL] [Abstract][Full Text] [Related]
2. T311--an anti-tyrosinase monoclonal antibody for the detection of melanocytic lesions in paraffin embedded tissues.
Jungbluth AA; Iversen K; Coplan K; Kolb D; Stockert E; Chen YT; Old LJ; Busam K
Pathol Res Pract; 2000; 196(4):235-42. PubMed ID: 10782467
[TBL] [Abstract][Full Text] [Related]
3. Tyrosinase immunoreactivity in formalin-fixed, paraffin-embedded primary and metastatic melanoma: frequency and distribution.
Hofbauer GF; Kamarashev J; Geertsen R; Böni R; Dummer R
J Cutan Pathol; 1998 Apr; 25(4):204-9. PubMed ID: 9609139
[TBL] [Abstract][Full Text] [Related]
4. The usefulness of tyrosinase in the immunohistochemical assessment of melanocytic lesions: a comparison of the novel T311 antibody (anti-tyrosinase) with S-100, HMB45, and A103 (anti-melan-A).
Clarkson KS; Sturdgess IC; Molyneux AJ
J Clin Pathol; 2001 Mar; 54(3):196-200. PubMed ID: 11253130
[TBL] [Abstract][Full Text] [Related]
5. Specification and use of a mouse monoclonal antibody raised against melanosomes for the histopathologic diagnosis of amelanotic malignant melanoma.
Maeda K; Maeda K; Jimbow K
Cancer; 1988 Sep; 62(5):926-34. PubMed ID: 3044572
[TBL] [Abstract][Full Text] [Related]
6. Value of dopachrome tautomerase detection in the assessment of melanocytic tumors.
Filimon A; Zurac SA; Milac AL; Sima LE; Petrescu SM; Negroiu G
Melanoma Res; 2014 Jun; 24(3):219-36. PubMed ID: 24709887
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical detection of melanoma-associated antigens on formalin-fixed, paraffin-embedded canine tumors.
Berrington AJ; Jimbow K; Haines DM
Vet Pathol; 1994 Jul; 31(4):455-61. PubMed ID: 7941235
[TBL] [Abstract][Full Text] [Related]
8. Tyrosinase and nestin immunohistochemical expression in melanocytic nevi as a histopathologic pattern to trace melanocyte differentiation and nevogenesis.
Murtas D; Pilloni L; Diana A; Casula L; Tomei S; Piras F; Ferreli C; Maxia C; Perra MT
Histochem Cell Biol; 2019 Feb; 151(2):175-185. PubMed ID: 30232588
[TBL] [Abstract][Full Text] [Related]
9. MAT-1, a monoclonal antibody that specifically recognizes human tyrosinase.
Takimoto H; Suzuki S; Masui S; Shibata K; Tomita Y; Shibahara S; Nakano H
J Invest Dermatol; 1995 Dec; 105(6):764-8. PubMed ID: 7490469
[TBL] [Abstract][Full Text] [Related]
10. hTERT expression in melanocytic lesions: an immunohistochemical study on paraffin-embedded tissue.
Fullen DR; Zhu W; Thomas D; Su LD
J Cutan Pathol; 2005 Nov; 32(10):680-4. PubMed ID: 16293180
[TBL] [Abstract][Full Text] [Related]
11. Positive reactivity of dysplastic melanocytes with a monoclonal antibody against melanoma melanosomes, MoAb HMSA-2.
Maeda K; Maeda K; Jimbow K
J Invest Dermatol; 1988 Sep; 91(3):247-50. PubMed ID: 3411143
[TBL] [Abstract][Full Text] [Related]
12. Proliferative activity of primary cutaneous melanocytic tumours.
Kuwata T; Kitagawa M; Kasuga T
Virchows Arch A Pathol Anat Histopathol; 1993; 423(5):359-64. PubMed ID: 7906909
[TBL] [Abstract][Full Text] [Related]
13. Development of MoAb HMSA-2 for melanosomes of human melanoma and its application to immunohistopathologic diagnosis of neoplastic melanocytes.
Maeda K; Jimbow K
Cancer; 1987 Feb; 59(3):415-23. PubMed ID: 3539311
[TBL] [Abstract][Full Text] [Related]
14. Heterogeneous expression of immunotherapy candidate proteins gp100, MART-1, and tyrosinase in human melanoma cell lines and in human melanocytic lesions.
de Vries TJ; Fourkour A; Wobbes T; Verkroost G; Ruiter DJ; van Muijen GN
Cancer Res; 1997 Aug; 57(15):3223-9. PubMed ID: 9242453
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of human monoclonal antibody (2-139-1) in cutaneous melanocytic neoplasms in fixed tissue sections.
White WL; Tam ST; Mitchell MS; Yu MC; Kan-Mitchell J
J Histochem Cytochem; 1991 Jun; 39(6):777-85. PubMed ID: 1709658
[TBL] [Abstract][Full Text] [Related]
16. Human monoclonal antibodies that distinguish cutaneous malignant melanomas from benign nevi in fixed tissue sections.
Imam A; Mitchell MS; Modlin RL; Taylor CR; Kempf RA; Kan-Mitchell J
J Invest Dermatol; 1986 Feb; 86(2):145-8. PubMed ID: 3528308
[TBL] [Abstract][Full Text] [Related]
17. Development of MoAb HMSA-3 and HMSA-4 against human melanoma melanosomes and their reactivities on formalin-fixed melanoma tissues.
Maeda K; Yamana K; Jimbow K
J Invest Dermatol; 1987 Dec; 89(6):588-93. PubMed ID: 3680982
[TBL] [Abstract][Full Text] [Related]
18. A murine monoclonal antibody, MoAb HMSA-5, against a melanosomal component highly expressed in early stages, and common to normal and neoplastic melanocytes.
Der JE; Dixon WT; Jimbow K; Horikoshi T
Br J Cancer; 1993 Jan; 67(1):47-57. PubMed ID: 7678981
[TBL] [Abstract][Full Text] [Related]
19. Detection of tyrosinase mRNA in formalin-fixed, paraffin-embedded archival sections of melanoma, using the reverse transcriptase in situ polymerase chain reaction.
Guo J; Cheng L; Wen DR; Huang RR; Cochran AJ
Diagn Mol Pathol; 1998 Feb; 7(1):10-5. PubMed ID: 9646029
[TBL] [Abstract][Full Text] [Related]
20. C-fos protein expression in Spitz nevi, common melanocytic nevi, and malignant melanomas.
Bergman R; Kerner H; Manov L; Friedman-Birnbaum R
Am J Dermatopathol; 1998 Jun; 20(3):262-5. PubMed ID: 9650699
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
